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Abstract: Bipolar disorder can be a devastating disease state for individuals with the disease 
and also for family members. Proper recognition and treatment is vital to the successful man-
agement of this disease state. Through increased community and practitioner awareness, along 
with efforts to increase awareness for proper assessment, the rate of diagnosed bipolar disorder 
is increasing. Recent years have brought about the introduction of several new medications with 
approved indications for the treatment of bipolar disorder. In addition to new agents, traditional 
mood stabilizing medications have also been released in different formulations to better enhance 
tolerability without jeopardizing efﬁ  cacy. One particular product is extended-release divalproex 
sodium. In the following article, we review the clinical presentation of bipolar disorder, its 
epidemiology, and the pharmacokinetics and mechanism of action for divalproex. In addition, 
we speciﬁ  cally review the role of extended-release divalproex in bipolar disorder through a 
critical analysis of the currently available published primary literature.
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Bipolar disorder
Bipolar disorder is a psychiatric disease state manifesting as two different mood 
extremes, mania and depression. Manic symptoms often include hyperactivity, hyper-
talkativeness, decreased need for sleep, grandiosity, increased risk taking, and being 
easily distracted (APA 2000). Depression symptoms typically consist of a depressed 
mood, decreased energy, feelings of guilt, hopelessness, helplessness, crying, and 
even suicidal ideations (APA 2000).
Symptoms of bipolar disorder typically present during late adolescence between the 
ages of 15 and 19 years, however it is not uncommon for proper diagnosis to be delayed 
for 5–10 years (Bowden et al 2002). Bipolar I disorder is estimated to be prevalent in 
1% of the US population, however recent ﬁ  ndings from a large-scale survey suggest 
an adjusted prevalence rate near 3.7% (Bowden et al 2002; Hirschfeld, Calabrese et al 
2003). Additionally, it has been found through survey that there is often a gap of up 
to 10 years between the ﬁ  rst visit and subsequent proper diagnosis, with the majority 
either not being diagnosed at all or inappropriately diagnosed with unipolar depres-
sion (Hirschfeld, Calabrese et al 2003; Hirschfeld, Lewis et al 2003). Identiﬁ  cation of 
which type of bipolar disorder is present is complicated by the fact that both bipolar I 
and bipolar II patients spend more time symptomatic in the depressed phase than the 
manic or hypomanic states (Judd et al 2002). This is signiﬁ  cant when considering the 
potential risk of switching a bipolar patient from a depressed state to manic state with 
antidepressant therapy. Contrary to this is that failure to address a depressive episode 
of bipolar disorder presents a dramatic increase in suicide risk. Additional things to 
consider when treating a patient with bipolar disorder are the high rates of concurrent 
substance abuse and anxiety disorders (Bowden et al 2002; McElroy 2004).Neuropsychiatric Disease and Treatment 2007:3(6) 840
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Valproate mechanism
The mechanism by which valproate exerts its therapeutic 
effect is not well understood. Several hypotheses have been 
proposed concerning the mechanism of action in epilepsy 
and bipolar disorder. The most well studied and understood 
mechanism of valproate is its ability to potentiate or mimic 
the effects of the inhibitory neurotransmitter, gamma-
aminobutyric acid (GABA) (Loscher 2002; Casey et al 
2003; Salloum et al 2005). Indirectly, this potentiation of 
GABA has been hypothesized to produce inhibitory effects 
on central dopamine (Casey et al 2002; Loscher 2002). Some 
of the other and less well understood mechanisms involve 
the inhibition of neuronal excitability and a resultant anti-
kindling effect (Loscher 2002). One speciﬁ  c area of study 
has focused on the inhibition of protein kinase C epsilon 
(PKC-epsilon) (Brunello 2004; Toth 2005). PKC-epsilon 
has been linked to the stimulation of intracellular calcium 
release and an increase in cortical excitation and instability. 
Valproate has also exhibited effects producing the block-
ade of voltage-dependent sodium channels (Loscher 2002; 
Owens and Nemeroff 2003). Another proposed mechanism, 
though controversial, is one likening valproate to lithium as a 
potential inhibitor of inositol synthesis through inhibition of 
myo-inositol-1phosphate (MIP) (Harwood and Agam 2003; 
Shaltiel et al 2004; Harwood 2005). It is not well understood 
if valproate inhibits MIP directly, but it has been shown to 
deplete inositol (Harwood and Agam 2003; Shaltiel et al 
2004; Harwood 2005).
Divalproex pharmacology
Delayed-release divalproex
Delayed-release divalproex (DR) is an enteric-coated com-
pound consisting of sodium valproate and valproic acid in 
a 1:1 molar ratio (Abbott Laboratories 2006). Divalproex 
is metabolized in the liver, primarily via glucuronidation 
to active metabolites, with the major active metabolite 
being Trans-2-en-valproate (Loscher 2002). The estimated 
half-life of divalproex ranges from 9 to 16 hours (Abbott 
Laboratories 2006). The usual dosing regimen for DR is on 
a two or three times daily schedule, often with the larger 
dose given at bedtime. The therapeutic range for divalproex 
sodium in acute mania according to primary literature 
suggests improvement is greatest at concentrations above 
50 μg/mL and that adverse effects increase signiﬁ  cantly 
at concentrations above 125 μg/mL (Bowden et al 2002). 
The more common side effects of DR are transient nausea 
(31%), asthenia (20%), somnolence (17%), dyspepsia (13%), 
dizziness (12%), diarrhea (12%), vomiting (11%), and tremor 
(9%) (Abbott Laboratories 2006). Some long-term side 
effects that have been associated with DR use are alopecia 
and weight gain. Therapeutic drug monitoring for valproic 
acid or any formulation of divalproex requires periodic 
monitoring of liver enzymes as serious liver toxicity has been 
reported, especially with use in children under the age of two 
and in patients receiving multiple antiepileptic medications. 
Valproic acid/divalproex have also been shown to produce 
a dose-related thrombocytopenia, thus periodic monitoring 
of platelets is also suggested. The primary advantage of the 
DR formulation over immediate release valproic acid (IR) 
is the enteric coating which helps reduce the incidence of 
gastrointestinal complaints. Prevalence of hepatic enzyme 
elevation, tremor, ataxia, increased appetite, weight gain, and 
alopecia have not been shown to be substantially different in 
clinical trials between DR and IR preparations.
Extended-release divalproex
The newest formulation of divalproex is in the form of an 
extended-release tablet, Depakote ER® (ER), which provides 
a once-daily administration option for the treatment of acute 
manic or mixed episodes of bipolar disorder, independent 
of the presence of psychotic features (Abbott Laboratories 
2006). The ER formulation uses a hydrophilic polymer matrix 
controlled-release tablet system to provide controlled contin-
ued release of medication. After oral administration and entry 
into the stomach, the outer coating of the tablet dissolves and 
exposes the polymer matrix. The outer layer of the matrix 
becomes hydrated and forms a gel layer from which drug is 
released. In addition to bipolar disorder, ER is also approved 
for the prophylactic management of migraine headaches in 
adults, as well as monotherapy and adjunctive therapy in 
adults and children 10 years of age and older with complex 
partial seizures, adults and children 10 years of age or older 
with simple and complex absence seizures, and adults and 
children 10 years of age and older with multiple seizure types 
including absence seizures (Abbott Laboratories 2006).
Comparative studies have shown that DR and ER are not 
bioequivalent products. The two primary kinetic differences 
are that the ER preparation results in an average bioavail-
ability of 81%–89% relative to DR and ER has produces a 
10%–20% lower ﬂ  uctuation in peak serum concentration as 
compared to DR (Abbott Laboratories 2006). These ﬁ  ndings 
suggest that when converting patients from DR to ER that 
the ER dose may need to be increased between 8% and 20% 
to produce an equivalent serum concentration.
Further evidence for pharmacokinetic differences were 
supported in a study using a healthy adult population and Neuropsychiatric Disease and Treatment 2007:3(6) 841
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comparing the bioavailability of unequal doses of DR and 
ER (Dutta et al 2002). The results from this study determined 
that daily doses of ER dosed 14% and 20% higher than DR 
(1000 mg/day ER vs 875 mg/day DR and 1500 mg/day ER 
vs 1250 mg/day DR) produced equivalent serum concentra-
tions as determined by area-under-the-curve (AUC) (Dutta 
et al 2002). The ER preparation resulted in a lower Cmax and 
a higher Cmin than corresponding DR doses. Peak-to-trough 
ﬂ  uctuations were 42%–48% lower for the ER preparation 
(Dutta et al 2002). This study also showed that the increase 
in dose required with the ER dosage form was well toler-
ated (Dutta et al 2002). While evidence is increasing, there 
continues to be a relative paucity of information available 
describing the use of ER in treating mood related symptoms 
within the psychiatric population.
Role of divalproex in bipolar 
disorder
There have been a number of recent additions to the list of 
approved medications for the treatment of bipolar disorder 
(see Table 1). Despite these new advancements in drug 
delivery and efﬁ  cacy for the treatment of bipolar disorder, 
DR continues to be a highly utilized mood stabilizer for 
the treatment of acute mania (Abbott Laboratories 2006). 
In many instances, bipolar disorder treatment guidelines 
recommend valproate as a preferred agent, with DR usu-
ally being the suggested formulation of valproate/valproic 
acid (divalproex) due to the presumed improved tolerability 
(Zarate et al 1999; Bowden et al 2002; Keck et al 2004; 
Suppes et al 2005). The disease states where evidence 
based guidelines support the use of valproate as a ﬁ  rst-line 
choice include: acute manic exacerbations, euphoric mania, 
dysphoric or mixed mania, and in patients being treated for 
rapid cycling bipolar disorder (see Table 2) (Bowden et al 
2002; Keck et al 2004; Suppes et al 2005). Valproate is also 
considered an appropriate agent for maintenance therapy, 
though it lacks the FDA maintenance indication (Taylor and 
Goodwin 2006). Other FDA approved indications for DR 
include the treatment of complex partial, simple absence, 
and complex absence seizures in addition to prophylaxis of 
migraine headaches (Abbott Laboratories 2006). DR is not 
FDA approved for aggression, though it is routinely used as 
monotherapy and is considered appropriate adjunct therapy 
to reduce hostility associated with schizophrenia (Citrome, 
Casey et al 2004; Lehman et al 2004).
Clinical trials – efﬁ  cacy
In order to identify published, primary literature studying 
the ER formulation in bipolar disorder we conducted an 
Ovid Medline search. Our search terms included bipolar 
disorder, mania, depression, extended-release divalproex, 
delayed-release divalproex, divalproex, and schizophrenia. 
We did not include any information that was not published 
in primary literature form so any “Data on File” with Abbott 
Laboratories that is not published is not included in this 
review. Our search yielded a small number of clinical tri-
als reporting on the use of extended-release divalproex in 
bipolar disorder. Three of the trials are open-label with a 
study enrollment ranging from 10 to 55 patients. The other 
three data sets included were published as “Letters to the 
Editor,” but were included for completeness of discussion. 
One additional study was included that examined the use 
Table 1 FDA approved medications for the treatment of bipolar disorder and their approved indications
FDA approved agents for management of bipolar disorder as of December 2006 
 Mania  Mixed  With  or  without  Maintenance  Bipolar
   episodes  psychotic  features    depression
Lithium (Eskalith®, Lithobid®) X      X 
Valproate (Depakote®) X       
Divalproex ER (Depakote ER®) X  X  X   
Carbamazepine ER (Equetro®) X  X     
Chlorpromazine (Thorazine®) X      
Olanzapine (Zyprexa®) X  X  X  X 
Risperidone (Risperdal®) X  X  X   
Quetiapine (Seroquel®) X        X
Ziprasidone (Geodon®) X  X  X   
Aripiprazole (Abilify®) X  X  X  X 
Lamotrigine (Lamictal®)       X 
Olanzapine/Fluoxetine (Symbyax®)         X
References: Bowden et al 2002; GlaxoSmithKline 2003, 2006; Keck et al 2004; Shire US Incorporated 2004; Pﬁ  zer 2005; Suppes et al 2005; Abbott Laboratories 2006; 
AstraZeneca 2006; Bristol-Myers Squibb 2006; Eli Lilly and Company 2006; Janssen 2006; Solvay Pharmaceuticals 2006.Neuropsychiatric Disease and Treatment 2007:3(6) 842
Stoner and Dahmen
of extended-release divalproex for mood stabilization and 
antipsychotic augmentation in schizophrenia.
The ﬁ  rst trial discussed is an open-label, seven day study 
evaluating the efﬁ  cacy and safety of converting psychiatric 
patients from DR to ER (Horne and Cunanan 2003). The 
majority of participants carried a diagnosis of bipolar disor-
der or major depression, 36% and 27% respectively. Other 
psychiatric diagnosis included schizophrenia and schizoaf-
fective disorder. A total of 55 patients were included in the 
conversion, 75% outpatients and 25% inpatients hospital-
ized for acute symptoms. Participants had been treated 
with DR from 2 days to 4 years at doses of 500 to 5,000 
mg/day. Concomitant medications were described and 
included agents such as antipsychotics, antidepressants, 
and anxiolytics.
Following baseline measurements of plasma valproic acid 
concentrations, study participants were switched to ER at a dose 
equal to their total daily dose of DR. Subsequent therapeutic 
drug monitoring included assessment of plasma valproic acid 
concentrations which were obtained 10 to 12 hours after the 
last dose on study days 3, 5, and 7. Over half the patients in the 
study (58%) experienced an increase in valproic acid plasma 
concentration when switched from DR to ER dosage forms. 
In all but three cases, plasma concentrations remained within 
the therapeutic range of 50–125 μg/mL. In two of the cases the 
plasma levels increased following the initiation of the ER dos-
age form with no signs of toxicity and returned to values within 
therapeutic range with dosage reduction. In the third case, the 
patient’s serum valproic acid level decreased below the lower 
limit of normal but increased following dosage titration.
Table 2 Suggested ﬁ  rst-line treatment strategies per available guidelines
Guidelines for the treatment of bipolar disorder
  Non-   Mixed   Dysphoric   Mania with   Euphoric   Psychotic   Bipolar 
  psychotic  mania  mania  a history of   mania  mania  depression
  mania       rapid cycling
APA    Severe: Li     Li OR VPA      Li OR LAM
    plus AP OR          
    VPA plus          
   AP        
    Less Severe:          
   monotherapy         
    Li, VPA or          
   AP        
Expert   Combination  Combo   Combination  Combination  MS  MS plus AP   LAM 
Consensus   MS plus AP  therapy and   treatment   treatment     OR   monotherapy
 2004   OR   monotherapy  and   and     monotherapy  OR LAM 
  monotherapy  received   monotherapy  monotherapy    AP  plus Li for 
   MS  equivalent   received   received       severe non-
    ratings  equivalent   equivalent       psychotic 
     ratings  ratings      depression 
             with  a 
             history  of 
             AD-induced 
             mania  or 
             rapid  cycling
TMAP   Monotherapy      Monotherapy    LAM  plus 
     VPA, ARP,       Li, VPA,     anti-manic 
    RIS, ZIP      ARP, QTP,     agent if 
          RIS, ZIP    recent and/or
             severe 
             history  of 
             mania,  all 
             other 
             patients 
             LAM 
             monotherapy
Abbreviation: AP, Antipsychotic; MS, Traditional Mood Stabilizer (carbamazepine, divalproex, lithium); Li, Lithium; VPA, Valproate; ARP, Aripiprazole; QTP, Quetiapine; RIS, 
Risperidone; ZIP, Ziprasidone; LAM, Lamotrigine; AD, Antidepressant.
References: Bowden et al 2002; Keck et al 2004; Suppes et al 2005.Neuropsychiatric Disease and Treatment 2007:3(6) 843
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Efﬁ  cacy was assessed with the Positive and Negative 
Syndrome Scale (PANSS) at baseline and endpoint. Upon 
analysis of the total patient population, a statistically 
signiﬁ  cant improvement was observed in mean PANSS 
total score, positive subscale and general psychopathology 
subscale from baseline to endpoint. Mean total PANSS scores 
at baseline were 71.5 ± 21.4 with a mean change of −4.3 ± 
11.1 at endpoint. While a statistical change was appreciated, 
clinical impact of improvement was most likely small.
Adverse events were assessed with the Udvalg for Kliniske 
Undersogelser (UKU) Side Effect Rating Scale. Patients reported 
a decrease in the number and severity of adverse effects at end-
point. Following the cessation of the study, 54 of the 55 partici-
pants choose to continue treatment with the ER formulation.
Statistical power was not discussed in the study design. 
This design characteristic becomes less of an issue for out-
come measures in which statistical improvement is observed. 
Overall, conversion from DR to ER in this inpatient and 
outpatient psychiatric population was not associated with 
deterioration in mental status. In addition, a reduction in both 
the incidence and severity of adverse effects was appreciated 
with the ER dosing formulation, most likely thought to be 
the result of lower peak concentrations.
A second published, open-label study highlighted the 
conversion of DR to ER in ten subjects over a four-week 
time period (Stoner et al 2004). Subjects were deemed 
eligible if they had been on DR at least 8 weeks and were 
considered “stable” in the two weeks preceding study enroll-
ment. Subjects were also required to be experiencing two 
“mild” adverse events or one “moderate” adverse event that 
was considered a potential side effect of DR. All subjects 
were using DR for mood or behavioral related symptoms, 
with most diagnosed with schizophrenia, bipolar disorder, 
or schizoaffective disorder, bipolar type. Additionally, eight 
subjects had a history of substance abuse.
Seven of the ten subjects were converted on an equal mil-
ligram-per-milligram basis, while the other three received a 250 
mg dose increase to 500 mg as at the time of the study only 500 
mg ER tablets were available. The mean DR dose at baseline 
was 2,475 ± 1,010 mg/day with a slightly higher mean dose of 
ER observed at study endpoint, 2,550 ± 985 mg/day. The study 
group included six males and four females with an average age of 
39.4 years and an average length of mental illness of 21.4 years. 
Subjects were diagnosed primarily with schizophrenia (n = 4), 
bipolar disorder (n = 2), and schizoaffective disorder (n = 2). 
Eight subjects had a history of substance abuse.
The primary outcome measure in this study was the 
18-item Brief Psychiatric Rating Scale (BPRS), selected 
to identify any changes in psychiatric, behavioral, or mood 
related symptoms. The BPRS was completed at baseline and 
then at Days 7, 14, 21, and 28. The results from this study 
demonstrated that subjects maintained psychiatric and mood 
stability. Of particular interest, no signiﬁ  cant changes were 
appreciated in weekly BPRS scores, although numerically 
the mean scores improved from baseline (29.10 ± 6.28) to 
endpoint (26.5 ± 7.14, p = 0.208). No individual BPRS items 
showed a statistically signiﬁ  cant change, however a trend 
suggested a decrease in somatic complaints (p = 0.057).
Eleven-hour post-dose valproic acid serum concentrations 
were collected at Days 14 and 28. No statistically signiﬁ  cant 
difference was found in DR baseline serum valproic acid 
concentrations (90.5 ± 29.11 μg/mL) and “Day 28” 11-hour 
post-dose ER valproic acid serum concentrations (95.50 ± 
13.68; p = 0.493). Additional monitoring parameters included 
assessment of weight changes, and collection hematologic, 
renal, hepatic, electrolyte, lipid, and glucose labs at baseline 
and study endpoint. No signiﬁ  cant changes in weight were 
observed between baseline and study endpoint. Serum chem-
istry monitoring showed statistically signiﬁ  cant decreases 
in LDL cholesterol and potassium, although the decline 
in potassium was not clinically signiﬁ  cant. There were no 
signiﬁ  cant changes in platelet counts observed during the 
course of the study. Tolerability and adverse event assess-
ment was as measured by the Systematic Assessment for 
Treatment Emergent Effects (SAFTEE) at baseline and then 
Days 7, 14, 21, and 28. SAFTEE results showed statistically 
signiﬁ  cant reductions in complaints of sedation, stomach and 
abdominal discomfort, and tremor from baseline to study 
endpoint. This study was limited by a small sample size and 
the inclusion of only stable patients, thus not allowing the 
clinical application the ER ﬁ  ndings to the acute phase of 
treatment. Additionally, the study subjects showed a broad 
variation of Axis I diagnosis, not limited to bipolar disor-
der. Despite these limitations, this study does provide some 
level of evidence that ER can be used in place of DR to help 
maintain psychiatric stability.
A third open-label, six day study was designed to com-
pare the conversion of stable bipolar I or II or schizoaffec-
tive subjects (n = 12) from the DR to the ER formulation 
(Centorrino et al 2003). Upon entry into the study, subjects 
were required to have baseline serum valproic acid levels 
within the therapeutic range of 50–120 μg/mL and had to 
have been receiving stable does of medications for at least 
four weeks prior to study initiation.
Participants were switched to ER with a goal of main-
taining stable valproic acid serum concentrations. As the Neuropsychiatric Disease and Treatment 2007:3(6) 844
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ER formulation was only available in the 500 mg tablet 
dosage form at the time of the study, doses were rounded 
to the nearest 500 mg/day. Serum valproic acid levels were 
collected at baseline, day 7, week 6, and one week following 
a medication adjustment. In this cohort of patients, it was 
observed that ER doses needed to be 20.7% higher than the 
previous DR doses to maintain serum valproic acid levels, a 
ﬁ  nding consistent with package labeling for ER.
Numerous efﬁ  cacy measurements were evaluated at 
baseline and weekly thereafter and included the Young 
Mania Rating Scale (YMRS), the 17-Item Hamilton Depres-
sion Rating Scale (HAM-D 17), Clinical Global Impres-
sion of severity (CGI-S) and improvement (CGI-I), Global 
Assessment of Functioning Scale (GAF), and the 17-item 
Brief Psychiatric Rating Scale (BPRS). The mean baseline 
YMRS score was 3.00 ± 3.86 and at endpoint it increased to 
3.42 ± 2.53. The baseline mean HAM-D 17 score was 11.2 ± 
9.3 and at endpoint the mean improved to 7.67 ± 6.97. The 
mean CGI of severity score at baseline was 2.58 ± 0.79 and 
at endpoint was 2.75 ± 0.65. The mean baseline GAF score 
was 68.3 ± 6.2 and at endpoint improved marginally with 
a value of 69.2 ± 6.0. The baseline mean BPRS score was 
39.8 ± 10.2 and at endpoint was 37.8 ± 7.82. None of the 
observed changes were deemed to be signiﬁ  cant in regards 
to psychiatric stability.
Tolerability was assessed using the UKU Side Effect Rat-
ing Scale for adverse effects. The most commonly reported 
adverse effects at both baseline and endpoint were impaired 
concentration, fatigue, depression, and decreased salivation. 
The only statistically signiﬁ  cant adverse event that was seen 
more frequently with the ER dosage form as compared to the 
DR was an increase in polyuria-polydipsia. All participants 
elected to continue treatment with the ER dosage formula-
tion at the conclusion of the study. This study was also not 
without limitations, most notably a small sample size and 
the inclusion of only stable patients.
Three small studies which have been published as “Letter 
to the Editors” are useful in reporting conversions from DR 
to ER dosage formulations in psychiatric outpatients (Longo 
2005; Minirth and Veal 2005; Jackson et al 2006). In the 
ﬁ  rst of these studies, a small, 12-week, open-label, pilot trial 
examined outpatients diagnosed with bipolar I or II disor-
der or schizoaffective disorder (Longo 2005). The patients 
described in this study were being treated with the DR for-
mulation, but were reporting associated adverse events. The 
dose conversion was carried out per package labeling which 
recommends up to a 20% dose increase in converting from 
DR to ER. No additional medication changes were allowed 
during the 12-week observation period. The primary outcome 
measures were the Clinical Global Impression Scale (CGI) 
and the Global Assessment of Functioning scales (GAF).
According to these outcome measures, 9 of 10 patients 
were considered to exhibit no change or slight improvement 
in their symptoms, while 5 of 10 reported improvements in 
adverse events. Baseline psychometric assessment scoring, 
dosing information, length of prior treatment, and therapeutic 
drug monitoring parameters were collected, however none of 
the values were reported. This study possesses several limita-
tions, however it does provide some information regarding 
practical experience with converting patients.
The second of the “Letter to the Editor” publications 
described a retrospective chart review that focused on the 
evaluation of efﬁ  cacy, tolerability, and impact on adherence 
when switching patients from DR to ER (Minirth and Veal 
2005). Psychiatric patients, including those diagnosed with 
bipolar disorder types I and II, were included. Participants 
eligible for enrollment had to have been taking DR for at 
least three months prior to the switch.
Patients were evaluated using the CGI-S scale on the day 
of the switch from DR to ER and again during the follow-up 
visit. Additional secondary assessments which were evalu-
ated at baseline and endpoint included Self-Rating Report of 
Symptoms and review of clinician’s notes regarding patient 
symptomatology.
The study was conducted at a single study site and 
included the records of 32 patients. Doses of divalproex 
sodium DR ranged from 125 to 1000 mg/day and following 
the milligram-for-milligram switch patients were maintained 
on 500–2000 mg/day of ER.
While this report suggests clinical improvement, the 
ability to critically evaluate the study is limited by a lack of 
data showing baseline and endpoint scores for the outcome 
measures. Therapeutic drug monitoring, particularly serum 
valproic acid levels, were not mentioned in the design of the 
study and were not reported. Adherence, one of the second-
ary outcome measures, was patient rated and evaluated by 
a telephone interview conducted by the raters. Statistical 
analysis was not performed on the data collected.
The third “Letter to the Editor” brieﬂ  y described the con-
version of 52 patients stabilized on DR who were converted 
on an equal milligram-per-milligram basis to the ER formula-
tion for up to 24 weeks (Jackson et al 2006). Psychometric 
assessment measures included the HAM-D 21 (21-item 
scale) and YMRS. Utilizing the statistical method of repeated 
measures analysis, statistically signiﬁ  cant improvement was 
noted from the time of conversion to study endpoint with Neuropsychiatric Disease and Treatment 2007:3(6) 845
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both the HAM-D 21 and YMRS. No signiﬁ  cant changes 
were identiﬁ  ed in therapeutic drug monitoring lab values 
and overall patients reported improved tolerability of the 
ER formulation.
The use of ER in the management of psychiatric symptoms 
has not been limited to bipolar disorder alone. One 4-week, 
open-label DR to ER conversion study included thirty patients 
diagnosed with schizophrenia (Citrome, Tremeau et al 2004). 
To be included in the study, patients had to be on a stable dose 
(1,000 to 3,000 mg/day) of DR for at least 4 weeks. Patients 
were converted at a 1:1 mg ratio (n = 12) for DR to ER if the 
baseline serum concentration of valproate was 85 μg/mL 
and 1:1.2 mg ratio (n = 18) for DR to ER if the baseline serum 
concentration of valproate was 85 μg/mL. Dosing required 
the use of 500 mg increments due to the lack of availability 
of the 250 mg tablet at the time of the study. The BPRS was 
the primary outcome measure with side effects assessed with 
the UKU Side Effect Rating Scale.
Twenty-seven of 30 patients completed the 4-week study. 
The baseline mean BPRS total score was 37.9 ± 9.2 (n = 30) 
and the mean endpoint BPRS score was 35.7 ± 11.2 (n = 29), 
producing a signiﬁ  cant mean reduction of 2.3 ± 5.4 points 
(p  = 0.0322). Signiﬁ  cant improvement was noted for the 
1:1 mg conversion group (p = 0.0561), but not for the 1:1.2 mg 
group (p = 0.2223). Mean UKU scores also showed signiﬁ  cant 
improvement, dropping from a mean of 8.8 ± 6.7 (n = 29) at 
baseline to 7.5 ± 5.8 (n = 28) at endpoint, though for patients 
with evaluable baseline and endpoint scores the mean change 
was a reduction of 2.2 ± 4.1 (n = 27, p = 0.0111).
The mean DR dose at study entry was 1,592 mg ± 498 
mg/day which produced a mean baseline trough (12-hours 
post-dose) valproate concentration of 80.1 ± 20.4 μg/mL. 
The ER dosing at study endpoint was 1,950 mg ± 592 mg/
day which produced a mean trough concentration (24-hours 
post-dose) of 73.1 ± 24.2 μg/mL. The 1:1 mg conversion 
group produced trough levels that were signiﬁ  cantly lower 
at endpoint compared to baseline (p = 0.0006), though the 
difference in baseline and endpoint levels for the 1:1.2 con-
version group were not (p = 0.7102).
The conversion of DR to ER was not associated with any 
reports of psychiatric decompensation. While the BPRS was 
noted to improve across the group, the small reduction should 
not be interpreted as being more effective as this study is lim-
ited by being open-label, small sample size, short duration, 
and the actual improvement was only a 6% reduction in total 
BPRS score. The improvement of UKU scores are consistent 
with other reports of improved tolerability associated with 
the ER formulation.
Conclusion
Current literature evaluating the use of ER in psychiatric 
patients with bipolar disorder suggests the ER formulation 
has advantages over the DR formulation. In contrast to DR, 
the ER formulation provides a dosage form of divalproex 
that is pharmacokinetically supported for once-daily dosing. 
While the studies included in this review were not speciﬁ  cally 
designed to examine differences in medication compliance 
rates, a correlation between once daily dosing and medica-
tion adherence has been established. Of additional beneﬁ  t, 
ER had improved tolerability over DR, likely the result of 
lower peak plasma concentrations without apparent risk 
of lost efﬁ  cacy.
The studies included in this review article are greatly lim-
ited when utilizing a strict evidence based medicine review 
procedure. The studies included are not blinded or controlled, 
they are limited by small sample sizes, they are of short-
duration, and are not powered. There is broad variation in 
the samples making cross-comparisons unreasonable. From 
a statistical standpoint, there is potential for a beta error, a 
declaration of no difference when a difference indeed exists, 
could result in a study not adequately designed to evaluate 
for mathematical signiﬁ  cance.
Despite these severe limitations, there is value in the 
information that has been reported in these study ﬁ  ndings. 
These studies provide practical practice information on 
converting from DR to ER in clinical settings and what can 
be expected in terms of efﬁ  cacy, tolerability, and therapeu-
tic drug monitoring. While there is no data indicating that 
the ER formulation provides any enhanced efﬁ  cacy over 
DR there is also no compelling data suggesting there is a 
risk to using the ER over the DR. formulation. The current 
treatment guidelines included in this review do not speciﬁ  -
cally recommend the ER formulation and from an evidence 
perspective one cannot say there is strong enough evidence 
to make it a ﬁ  rst-line choice over other treatment options. 
However, given that the molecule is the same (divalproex) 
and that the primary differences are rate of release and a 
reduced peak concentration, the ER formulation should be 
considered a safe alternative to DR, particularly when there 
is a history or concern of dose related (peak concentration) 
adverse events or when once a day dosing is preferred in an 
effort to enhance compliance.
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